- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00384956
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Myelodysplastic syndrome (MDS) is a hematological disorder characterized by ineffective hematopoiesis. The only known curative treatment for patients with MDS is allogeneic stem cell transplantation. However, only a minority of patients are candidates for this aggressive therapy. DNA hypomethylation agents have been shown to have activity in this disorder and are postulated to work by reversing this epigenetic mechanism of gene-silencing. Recently, 5-azacitidine, administered subcutaneously for seven days, received approval by the FDA for the therapy of MDS based on a randomized trial which demonstrated a diminished risk of leukemic transformation and improved survival when compared to best supportive care.
The subcutaneous route of administration can present challenges to implementing this therapy. In the CALGB studies 8921 and 9221, approximately 23% of patients had significant injection site pain. Moreover, 35 % of patients had injection site bruising which can be extensive in thrombocytopenic patients. Due to limitations on drug concentration and administration volumes for subcutaneous dosing, patients often need to have two or three injections at separate sites each day to meet target dosing. In addition, the schedule of administration is inconvenient in an outpatient setting secondary to the need to schedule administrations over weekends. Therefore, there is great interest in pursuing an abbreviated intravenous route for administration of the drug.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
Missouri
-
St. Louis, Missouri, Vereinigte Staaten, 63110
- Washington University School of Medicine
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
Pathological MDS either de novo or secondary, fitting any of the FAB classifications, confirmed by institutional pathologist within 2 weeks prior to start of treatment. Patients with 5% bone marrow blasts must also meet one of the following criteria:
- Symptomatic anemia with either hemoglobin less than 10.0 g/dL or requiring RBC transfusion
- Thrombocytopenia with a history of two or more platelet counts < 50,000 / µL or a significant hemorrhage requiring platelet transfusions, or
- Neutropenia with two or more absolute neutrophil counts less than 1,000 /µL.
- ECOG performance status of 0-2.
- Must give written informed consent indicating their awareness of the investigational nature of this study and its potential hazards.
- Adequate renal and hepatic function (creatinine ≤ 150% of institutional upper limit of normal, total bilirubin ≤ 150% institutional upper limit of normal, AST ≤ 200% institutional upper limit of normal).
- Life expectancy of at least 12 weeks.
- Have not received any chemotherapy within 4 weeks of study enrollment and must have recovered from any treatment-related toxicities.
- Women of childbearing age must have a negative serum pregnancy test prior to initiating therapy.
- Sexually active women of childbearing potential must use effective birth control during the trial and for an appropriate period after the trial.
- Men must be willing to avoid fathering a new child while receiving therapy with azacitidine.
- ≥18 years, no upper age limit
- Individuals who are candidates for hematopoietic stem cell transplantation and who meet all other study criteria may participate in the study and receive intravenous azacitidine alone as a treatment prior to transplantation.
Exclusion Criteria:
- Known CNS leukemia.
- Previously received Azacitidine (Vidaza®, Pharmion Corp., Boulder CO) or decitabine (Dacogen®, MGI Pharma Inc. Bloomington, MN).
- Known or suspected hypersensitivity to azacitidine or mannitol.
- Receiving any other investigational agents within 30 days of first dose of study drug.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, congestive heart failure of NYHA class 3 or 4, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
- Known positive serology for HIV.
- Had radiotherapy within 14 days prior to study enrollment.
- Known presence of hepatic tumors.
- <18 years of age
- Exclude women who are pregnant or breast feeding.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Azacitidine
Azacitidine 75 mg/m2 IV on days 1-5 of each 28 day cycle.
Patients that do not respond after two cycles will have the dose increased to 100 mg/m2.
Patients who achieve a CR will receive 3 additional 28 day cycles and then begin treatment on days 1-5 of a 56 day cycle.
Individuals who demonstrate a loss of response will resume 28 day cycles.
|
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Rate of Complete Remission (CR) and Partial Remission (PR)
Zeitfenster: After 4 cycles of therapy (up to 112 days after start of treatment)
|
Defined according to the modified International Working Group (IWG) (2006) response criteria for myelodysplasia: CR=bone marrow with <5% myeloblasts and 0% peripheral blasts, hemoglobin ≥11g/dL, platelets ≥ 100 x 10^9/L, and neutrophils ≥1.0 x 10^9/L. Residual dysplasia was allowed. PR= All of the CR criteria if abnormal before treatment except: bone marrow blasts decreased by ≥50% over pretreatment but still >5%. |
After 4 cycles of therapy (up to 112 days after start of treatment)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Rate of Hematologic Improvement
Zeitfenster: 4 weeks following last azacitidine dose [median number of cycles 4.5 (1-20)]
|
International Working Group (IWG) for Myelodysplasia (MDS).
|
4 weeks following last azacitidine dose [median number of cycles 4.5 (1-20)]
|
Rate of Transfusion Independence
Zeitfenster: 4 weeks following last azacitidine dose [median number of cycles 4.5 (1-20)]
|
4 weeks following last azacitidine dose [median number of cycles 4.5 (1-20)]
|
|
Rate of Cytogenetic Response
Zeitfenster: 2 years after first dose of study drug or until participant is lost to follow-up or dies
|
2 years after first dose of study drug or until participant is lost to follow-up or dies
|
|
Rate of Overall Survival
Zeitfenster: 2 years after first dose of study drug or until participant is lost to follow-up or dies
|
Overall survival is defined as the date of first dose of study drug to the date of death from any cause.
|
2 years after first dose of study drug or until participant is lost to follow-up or dies
|
Rate of Relapse After Hematopoietic Stem Cell Transplant in Individuals Treated With 5-azacitidine Prior to Transplant.
Zeitfenster: 2 years after first dose of study drug or until participant is lost to follow-up or dies
|
2 years after first dose of study drug or until participant is lost to follow-up or dies
|
Mitarbeiter und Ermittler
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen
- Erkrankung
- Erkrankungen des Knochenmarks
- Hämatologische Erkrankungen
- Krebsvorstufen
- Syndrom
- Myelodysplastische Syndrome
- Präleukämie
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antimetaboliten, antineoplastisch
- Antimetaboliten
- Antineoplastische Mittel
- Azacitidin
Andere Studien-ID-Nummern
- 06-0585
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Myelodysplastische Syndrome
-
University of Colorado, DenverRekrutierungKlinefelter-Syndrom | Trisomie X | XYY-Syndrom | XXXY- und XXXXY-Syndrom | Xxyy-Syndrom | Xyyy-Syndrom | Xxxx-Syndrom | Xxxxx-Syndrom | Xxxyy-Syndrom | Xxyyy-Syndrom | Xyyyy-Syndrom | Männchen mit GeschlechtschromosomenmosaikVereinigte Staaten
-
Riphah International UniversityAbgeschlossen
-
Riphah International UniversityAbgeschlossen
-
Shaare Zedek Medical CenterUnbekanntPrämenstruelles Syndrom-PMS
-
Esra ÖZERKTO Karatay UniversityRekrutierungPrämenstruelles Syndrom-PMSTruthahn
-
Assistance Publique - Hôpitaux de ParisRekrutierungIntensivstation-Syndrom | Pädiatrisches Post-Intensivpflege-SyndromFrankreich
-
Riphah International UniversityRekrutierungUpper-Cross-SyndromPakistan
-
Cairo UniversityNoch keine Rekrutierung
-
Cairo UniversityRekrutierung
-
Riphah International UniversityRekrutierungUpper-Cross-SyndromPakistan
Klinische Studien zur Azacitidin
-
Shandong Provincial HospitalUnbekanntMyelodysplastische Syndrome, akute myeloische LeukämieChina
-
TJ Biopharma Co., Ltd.Rekrutierung
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Celgene CorporationAbgeschlossenMyelodysplastische Syndrome (MDS) | Akute myeloische Leukämie (AML)Australien
-
Navy General Hospital, BeijingRekrutierungRefraktäres klassisches Hodgkin-Lymphom | Rezidiviertes klassisches Hodgkin-LymphomChina
-
Nanexa ABUppsala UniversityAbgeschlossenMyelodysplastische Syndrome (MDS) | Akute myeloische Leukämie (AML) | Chronische myelomonozytäre Leukämie (CMML)Schweden
-
CelgeneAbgeschlossenMyelodysplastische Syndrome (MDS) | Chronische myelomonozytäre Leukämie (CMML) | Akute myeloische Leukämie (AML)Vereinigte Staaten
-
University of BirminghamRekrutierungAkute myeloische Leukämie | MyelodysplasieVereinigtes Königreich
-
Bristol-Myers SquibbRekrutierungMyelodysplastische SyndromeVereinigte Staaten, Japan, Argentinien, Hongkong, Griechenland, Italien, China, Australien, Spanien, Österreich, Dänemark, Deutschland, Schweden, Schweiz, Kanada, Tschechien, Korea, Republik von, Polen, Truthahn, Frankreich
-
CelgeneAbgeschlossenMyelodysplastische Syndrome | Leukämie, myeloisch, akut | Leukämie, myelomonozytär, chronischVereinigte Staaten
-
Groupe Francophone des MyelodysplasiesMerck Sharp & Dohme LLCBeendetMyelodysplastisches SyndromFrankreich